


AQEMIA

TECH-POWERED DRUG
DISCOVERY, ROOTED IN
FUNDAMENTAL PHYSICS
AND GENERATIVE AI

AQEMIA originates from deep-physics research and combines proprietary, physics-based algorithms with next-generation generative AI.

The platform enables preclinical drug discovery across oncology, immunology, neurology, and cardiology, with a focus on designing truly novel drug candidates over me-too compounds.

KEY FIGURES & MILESTONES



2019

Founded as a deeptech spin-off from fundamental research in statistical and quantum mechanics



12+ years

Research at CNRS, École Normale Supérieure, Oxford and Cambridge




2 Offices

Paris (FR) & London (UK)



40+ scientific articles

On AQEMIA's proprietary method



70+ employees

A multidisciplinary team blending science, tech & pharma expertise



\$100M Funding

\$70M in 2024 – Cathay Innovation, Wendel, Bpifrance, Eurazeo, Elaia

PIPELINE & COLLABORATION

50+ active programs

Most advanced programs showing efficacy in cancer animal models

Strategic Partnerships

With Servier, J&J & Sanofi — including a \$150M multi-year deal with Sanofi in 2024

FOUNDERS

**Maximilien
Levesque, PhD**

CEO



**Emmanuelle
Martiano-Rolland**

COO

